Latest News

Analysis Finds Low Malignancy Rate in Pediatric Longitudinal Melanonychia


 

TOPLINE:

Despite a high frequency of atypical features, longitudinal melanonychia (LM) in children is associated with an exceedingly low rate of malignancy.

METHODOLOGY:

  • LM — a pigmented band in the nail plate caused by increased melanin deposition — occurs in children and adults, resulting from melanocytic activation or proliferation in response to infection, systemic disease, medication, trauma, and other factors.
  • Clinical features of LM in children mimic red-flag signs of subungual melanoma in adults although rarely is subungual melanoma.
  • A biopsy can confirm the diagnosis, but other considerations include the scar, cost and stress of a procedure, and possibly pain or deformity.
  • The researchers conducted a systematic review and meta-analysis of the prevalence of clinical and dermoscopic features in 1391 pediatric patients with LM (diagnosed at a mean age of 5-13 years) from 24 studies published between 1996 and 2023.

TAKEAWAY:

  • Of 731 lesions in which a diagnosis was provided, benign nail matrix nevus accounted for 86% of cases.
  • Only eight cases of subungual melanoma in situ were diagnosed, with no cases of invasive melanoma identified.
  • Most lesions occurred on the fingernails (76%), particularly in the first digits (45%), and the most frequent clinical features included dark-colored bands (70%), multicolored bands (48%), broad bandwidth (41%), and pseudo-Hutchinson sign (41%).
  • During a median follow-up of 1-5.5 years, 30% of lesions continued to evolve with changes in width or color, while 23% remained stable and 20% underwent spontaneous regression.

IN PRACTICE:

“In the pivotal clinical decision of whether to biopsy a child with longitudinal melanonychia, perhaps with features that would require a prompt biopsy in an adult, this study provides data to support the option of clinical monitoring,” the authors wrote.

SOURCE:

The meta-analysis, led by Serena Yun-Chen Tsai, MD, in the Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, was published online in Pediatric Dermatology.

LIMITATIONS:

Most studies were conducted in Asia, and data stratified by skin type were limited. Inconsistent reporting and missing critical features could affect data quality. Also, certain features displayed high heterogeneity.

DISCLOSURES:

This meta-analysis was supported by the Pediatric Dermatology Research Alliance Career Bridge Research Grant. One co-author disclosed relationships with UpToDate (author, reviewer), Skin Analytics (consultant), and DermTech (research materials).

A version of this article appeared on Medscape.com.

Recommended Reading

Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
MDedge Hematology and Oncology
New Trials in Leukemia and Lymphoma: Could Your Patient Benefit?
MDedge Hematology and Oncology
FDA Removes Harmful Chemicals From Food Packaging
MDedge Hematology and Oncology
Pfizer Antibody-Drug Conjugate Picks Up Pediatric ALL Indication
MDedge Hematology and Oncology
Does Exercise Reduce Cancer Risk? It’s Just Not That Simple
MDedge Hematology and Oncology
New Drug Approvals Are the Wrong Metric for Cancer Policy
MDedge Hematology and Oncology
Most Cancer Trial Centers Located Closer to White, Affluent Populations
MDedge Hematology and Oncology
Few Childhood Cancer Survivors Get Recommended Screenings
MDedge Hematology and Oncology
Should Opioids Be Used for Chronic Cancer Pain?
MDedge Hematology and Oncology
Virtual Reality Brings Relief to Hospitalized Patients With Cancer
MDedge Hematology and Oncology